Business of Science

at the business of science® the intersection between bioscience startups and the financial sector must be transparent and not siloed within their respective industries. the business of science® has pioneered due diligence, risk assessment rating score utilizing an ai platform that works within the intersect of the biotech and fintech, titled the boss biofin score®. the boss biofin score®’s predictive analytics increases startup's valuation, an investor’s return on investment, and accelerates health care discoveries to market by 75%. we believe due diligence and de-risking processes should be simple, and accessible to both sides of innovation and not siloed within the bioentrepreneur or investor industries. score is a structured approach to identify and value a startup's innovation by considering the entire value chain, starting at conception, and ending it after-sales service and including support functions. through our decision management ecosystem technology, we are committed to